口服普萘洛尔对婴幼儿血管瘤患儿血糖影响的初步研究

• 作 者: 陶超 刘海金 彭威 黄海金 许露 阎金龙 黄皓瀚 刘潜 何晓东
• 机 构: 赣南医学院第一附属医院小儿外科,广东省妇幼保健医院,赣南医学院基础医学院,重庆市金童佳儿童医院,
• 出 处: 中国小儿血液与肿瘤杂志
• 发表日期: 2016年03期
• 关键词: 婴幼儿血管瘤 普萘洛尔 血管瘤 维持剂量 连续监测 有显著性差异 低血糖 消退期 剂量 平均血糖水平

目的探讨口服普萘洛尔治疗血管瘤患儿血糖的变化情况。方法我院2013年1月-{2014年12月69例婴幼儿血管瘤患儿,口服普萘洛尔治疗,将普萘洛尔均分为3份在三餐餐后短时间内服用,服药1h后监测血糖,梯度加量,连续监测3d,直至2mg/(kg·d)的维持剂量。结果服药前,所有患儿血糖在正常范围。服用不同剂量的普萘洛尔对血糖无明显影响。1例患儿服药第2d血糖下降至3.8 mmol/L,低血糖发生率为1.4%。结论通过连续性监测,口服普萘洛尔治疗的血管瘤患儿血糖未发现有显著性差异的变化,初步提示我们的临床用法相对安全,但仍需进一步深入研究。

Objective To investigate the changes of blood glucose in children treated with propranolol orally. Methods In our hospital from January 2013 to December 2014, 69 children with infantile hemangioma were treated with propranolol orally. Propranolol was divided into three groups taking shortly after meals, Blood glucose and blood glucose were monitored after 1h, and were monitored continuously for 3d until the maintenance dose of 2mg / (kg · d). Results before taking all children with blood glucose in the normal range. Taking different doses of propranolol had no significant effect on blood glucose. One patient had a decrease in blood glucose to 3.8 mmol / L on day 2 and a 1.4% incidence of hypoglycemia. Conclusion No significant difference was found in the blood glucose of propranolol treated hemangiomas by continuous monitoring, which initially suggested that our clinical application is relatively safe. However, further study is needed.